Press-release for stocks for NVS

symbols : NVS

save search

Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
Published: 2023-06-12 (Crawled : 06:00) - globenewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -7.78% | O: -0.16% H: 0.11% C: -0.76%
KDNY | $40.39 0.22% -0.17% 0

Health Technology

| 68.36% | O: 57.44% H: 0.98% C: 0.55%
novartis therapeutics acquired agreement

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Published: 2022-03-08 (Crawled : 17:00) - voyagertherapeutics.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 11.07% | O: -4.98% H: 0.0% C: 0.0%
VYGR | $7.74 -3.01% -2.84% 640K

Health Technology

| 111.48% | O: 31.15% H: 19.58% C: 9.17%
therapeutics report results

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Published: 2022-03-08 (Crawled : 07:00) - globenewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 11.07% | O: -4.98% H: 0.0% C: 0.0%
VYGR | $7.74 -3.01% -2.84% 640K

Health Technology

| 111.48% | O: 31.15% H: 19.58% C: 9.17%
trace novartis aav capsids gene therapy program license therapeutics therapy

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 7.77% | O: -1.03% H: 0.24% C: -0.15%
BGNE S | $131.86 -1.63% -1.64% 180K

Health Technology

| -48.93% | O: 8.83% H: 0.11% C: -4.16%
novartis license immunotherapy therapy collaboration

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $25.42 -1.05% 0.16% 40M

Health Technology

| -37.06% | O: 0.37% H: 0.2% C: -0.79%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 11.35% | O: 6.51% H: 1.75% C: 1.4%
kisqali breast cancer novartis trial

Clostridium Diagnostics Market to grow at a CAGR of 13.69% from 2022 to 2027, Driven by the growing prevalence of CDI - Technavio
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
AZNCF | $140.15 3.58% -4.19% 560

Health Technology

| -1.02% | O: 0.55% H: 1.46% C: -0.08%
TMO | News | $547.25 -1.32% -1.51% 1.2M

Health Technology

| -1.97% | O: 0.99% H: 0.78% C: -0.37%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 11.35% | O: 6.51% H: 1.75% C: 1.4%
TRIB | $1.84 -0.81% 1.08% 3.1K

Health Technology

| 96.79% | O: 1.6% H: 0.0% C: -6.32%
AZN | $68.53 0.39% 0.39% 3.2M

Health Technology

| 0.52% | O: 1.46% H: 0.53% C: -0.25%
growing diagnostics market

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $20.05 2.82% 2.26% 100K

n/a

| -10.51% | O: 6.23% H: 2.77% C: -10.21%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -3.42% | O: 0.47% H: 0.23% C: -0.99%
pharma business

Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| 17.24% | O: 6.92% H: 0.0% C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 15.3% | O: 5.97% H: 0.0% C: 0.0%
novartis growth

Insights on the Advanced Therapy Medicinal Products Global Market to 2027 - Featuring Bluebird Bio, Celgene and Gilead Lifesciences Among Others
Published: 2021-04-26 (Crawled : 14:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 5.45% | O: -0.17% H: 0.11% C: -0.35%
VCEL | $46.26 -2.65% -2.66% 320K

Health Technology

| -22.37% | O: 1.11% H: 6.59% C: 6.31%
QURE | $4.67 -0.64% -0.64% 830K

Health Technology

| -85.53% | O: 5.7% H: 4.95% C: 2.43%
BLUE | $0.9633 -2.73% -2.43% 8.4M

Health Technology

| -96.54% | O: 1.19% H: 2.0% C: 1.69%
therapy

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Published: 2023-03-06 (Crawled : 12:00) - ir.voyagertherapeutics.com
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| 34.89% | O: 2.04% H: 0.0% C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 9.92% | O: 0.34% H: 0.76% C: -0.06%
VYGR | $7.74 -3.01% -2.84% 640K

Health Technology

| 5.88% | O: 5.47% H: 5.45% C: 3.24%
disease license therapeutics payment

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Published: 2023-04-25 (Crawled : 15:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| 12.37% | O: 5.0% H: 0.0% C: -0.57%
ERAS | $1.84 -4.66% -4.61% 580K

| -28.52% | O: 0.0% H: 2.59% C: -3.7%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -7.47% | O: 4.24% H: 0.68% C: -0.77%
melanoma publication potential

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -11.12% | O: -0.11% H: 0.72% C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M

Health Technology

| -21.28% | O: 6.91% H: 1.49% C: -2.49%
INCY | $52.72 -0.94% -0.91% 2.1M

Health Technology

| -20.79% | O: 0.03% H: 0.17% C: -1.19%
BNTX | $86.4 0.07% 0.09% 1.2M

Health Technology

| -20.37% | O: 4.23% H: 0.0% C: -4.4%
ADAP | $0.987 -4.18% -3.23% 1.2M

Health Technology

| -26.43% | O: 1.43% H: 2.11% C: -1.41%
companies report cancer pancreatic global

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Published: 2022-07-19 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| 35.67% | O: 3.55% H: 0.0% C: -0.01%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 12.55% | O: 4.22% H: 0.26% C: -0.22%
novartis momentum growth group

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 290

Health Technology

| 4.69% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | $140.15 3.58% -4.19% 560

Health Technology

| 3.09% | O: 3.41% H: 0.0% C: -2.45%
VTRS | $11.1 -0.18% -0.23% 4.7M

Health Technology

| -6.01% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -13.61% | O: -2.04% H: 0.19% C: -1.97%
GSK | $39.6 -0.88% 0.03% 2.6M

Health Technology

| 1.3% | O: 4.04% H: 1.57% C: -3.02%
ABBV | $164.25 1.05% 0.26% 3M

Health Technology

| -0.6% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.11 0.68% 0.7% 3.5M

Health Technology

| -8.28% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $5.17 1.37% 1.54% 250K

Health Technology

| 8.5% | O: -0.1% H: 2.31% C: -1.26%
AZN | $68.53 0.39% 0.39% 3.2M

Health Technology

| 1.58% | O: 0.82% H: 0.12% C: -1.64%
AMGN | $264.07 -0.59% -0.59% 1.6M

Health Technology

| -15.16% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | News | $9.594 1.2% 43.47% 0

Health Technology

| -16.94% | O: 4.34% H: 0.0% C: 0.0%
GLAXF | $20.2 0.65% -14.18% 290

Health Technology

| 4.69% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | $140.15 3.58% -4.19% 560

Health Technology

| 3.09% | O: 3.41% H: 0.0% C: -2.45%
ALPMY | News | $9.46 1.29% -1.11% 500K

Manufacturing

| -19.27% | O: 0.0% H: 1.38% C: 0.26%
VTRS | $11.1 -0.18% -0.23% 4.7M

Health Technology

| -6.01% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| -13.61% | O: -2.04% H: 0.19% C: -1.97%
GSK | $39.6 -0.88% 0.03% 2.6M

Health Technology

| 1.3% | O: 4.04% H: 1.57% C: -3.02%
ABBV | $164.25 1.05% 0.26% 3M

Health Technology

| -0.6% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $46.11 0.68% 0.7% 3.5M

Health Technology

| -8.28% | O: 1.75% H: 0.0% C: 0.0%
AZN | $68.53 0.39% 0.39% 3.2M

Health Technology

| 1.58% | O: 0.82% H: 0.12% C: -1.64%
market

Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight
Published: 2022-06-06 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K

Health Technology

| 25.8% | O: -1.87% H: 2.91% C: 2.91%
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 4.21% | O: 0.31% H: 0.0% C: -1.04%
LLY | News | $750.77 0.54% 0.22% 2.8M

Health Technology

| 147.75% | O: 3.83% H: 0.0% C: 0.0%
OMER | $3.34 -2.62% -3.31% 270K

Health Technology

| 33.6% | O: 0.8% H: 2.78% C: -13.1%
lupus market

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 6.4% | O: -0.39% H: 0.15% C: -1.07%
INCY | $52.72 -0.94% -0.91% 2.1M

Health Technology

| -32.05% | O: 3.73% H: 0.09% C: -3.98%
jakavi treatment disease approval

Global Microarray Market Report 2022: Large-Scale DNA/Gene Chip Initiatives to Drive Sector Moving Forward
Published: 2022-11-09 (Crawled : 21:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology

| 12.19% | O: 2.81% H: 0.43% C: -0.2%
MDT | News | $79.08 -0.22% 0.25% 4.6M

Health Technology

| -0.26% | O: 3.56% H: 0.11% C: -0.33%
ABBV | $164.25 1.05% 0.26% 3M

Health Technology

| 11.05% | O: 2.06% H: 0.0% C: -0.62%
ABT | News | $105.9 -3.03% 0.38% 11M

Health Technology

| 8.52% | O: 3.59% H: 1.37% C: 1.16%
global report chip market

Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | News | $93.08 -0.13% 0.13% 1.1M

Health Technology